CDKN2A and neoplasm: Although variation in genes such as NF1, CDKN2A/B, TP53, and SUZ12 and/or EED are found in most MPNST, the precise order and timing of these changes remain poorly described, and this may be important for understanding the early stages of tumor development and/or the development of treatment resistance.